MEDERA

What this means for you

Not registered yet, but its 11 Feb 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99036193

Mark type

Stylized text

Filed

11 Feb 2025

Attorney of record

Anna Kurian Shaw

Goods and services

• Class 042 — Scientific and technological services: Bacteriological research for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Biological research for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Biomedical research services for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Chemical research for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Scientific research in the nature of conducting clinical trials for others; Conducting early evaluations for others in the field of new pharmaceuticals for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Development of biopharmaceutical preparations and medicines for gene and cell therapies for others for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Drug discovery services for others; Engineering services for others, particularly technical project planning and design engineering of lines for the processing of web products; Industrial research for others in the field of regenerative and reparative gene and cell therapies; Medical research laboratory services for others; Pharmaceutical research services for others; Pharmaceutical drug development services for others for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Pharmaceutical product evaluation for others; Providing medical and scientific research information for others in the field of pharmaceuticals and clinical trials; Research and development of new products for others; Research and development of vaccines and medicines for gene and cell therapies for others for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Scientific research for others in the field of gene therapy; Stem cell research services for others; Technical research for others in the field of pharmaceutical studies; Technology research for others in the field of regenerative gene and cell therapies
• Class 044 — Medical, beauty and agricultural services: Blood bank services; Human tissue bank services; Organ and tissue bank services; Stem cell therapy services; Medical services; Consultancy in the field of the medical treatment and diagnosis of cardiovascular diseases

Owner

• Medera Inc., Boston, MA, KY

Prosecution history

• 21 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 21 Jan 2026 — NON-FINAL ACTION E-MAILED
• 21 Jan 2026 — NON-FINAL ACTION WRITTEN
• 16 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 16 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 16 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 13 Oct 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 13 Oct 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 18 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 18 Jul 2025 — NON-FINAL ACTION E-MAILED
• 18 Jul 2025 — NON-FINAL ACTION WRITTEN
• 18 Jul 2025 — ASSIGNED TO EXAMINER
• 09 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 11 Feb 2025 — APPLICATION FILING RECEIPT MAILED
• 11 Feb 2025 — NEW APPLICATION ENTERED